Rephonic
Artwork for The BioCentury Show

The BioCentury Show

BioCentury
FDA
Biotechnology
Clinical Trials
Drug Pricing
Drug Development
China
Artificial Intelligence
Biotech
Biologics
Gene Therapy
Pharmaceutical Industry
Biosimilars
Inflation Reduction Act
Cancer Treatments
Novartis
Oncology
Mergers and Acquisitions
Immunology
Drug Regulation
Private Equity

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.

Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.

The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how scien... more

PublishesTwice monthlyEpisodes72Founded2 years ago
Number of ListenersCategories
Life SciencesBusinessScience

Listen to this Podcast

Artwork for The BioCentury Show

Latest Episodes

Untapped multibillion-dollar markets are hiding in plain sight where patients endure mediocre generic standards of care, according to Canaan General Partner Julie Grant, co-founder and first CEO of Day One, which Servier acquired for $2.5 billion thi... more

On this edition of The BioCentury Show, Nick Galakatos, Global Head of Life Sciences at Blackstone, joins Editor in Chief Simone Fishburn to discuss the path from Clarus to Blackstone's new $6.3 billion fund, and the goal of game-changing bets.

Galak... more

YouTube

On This Edition of The BioCentury Show, Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins BioCentury’s Tierney Baum to discuss genetics as a scalable drug discovery platform and the practical u... more

YouTube

The Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies as the starting point for a development framework that could eventually extend across all genetically defined diseases. The initiative seeks to br... more

YouTube

Key Facts

Accepts Guests
Accepts Sponsors
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Biotech Hangout
Biotech HangoutDaphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
Ground Truths
Ground TruthsEric Topol

Recent Guests

Nick Galakatos
Global Head of Life Sciences at Blackstone; Chairman of its Investment Committees
Blackstone Life Sciences
Episode: Ep. 119 - Blackstone's Galakatos on funding biotech's hardest mile
Gonçalo Abecasis
Vice President and Chief Genomics and Data Sciences Officer, Regeneron Genetics Center
Regeneron
Episode: Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets
Jessica Owens
Partner at Initiate Ventures, AI-native healthcare investor and co-founder
Initiate Ventures
Episode: Ep. 115 - Initiate's Owens on what it takes to be AI-native
Frank Jiang
EVP and Chief Strategy Officer of Hengrui Pharmaceuticals
Hengrui Pharmaceuticals
Episode: Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking
Chris Arendt
Chief Scientific Officer at Takeda
Takeda
Episode: Ep. 112 - Chris Arendt on rebuilding Takeda for AI
Angela Genge
Physician researcher, neurologist, and McGill University professor; Chief Medical Officer at ALS Pharma
McGill University; ALS Pharma
Episode: Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner
Karen Knudsen
CEO of the Parker Institute for Cancer Immunotherapy
Parker Institute for Cancer Immunotherapy
Episode: Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development
Chris Hollowood
CEO of Syncona Investment Management Limited
Syncona Investment Management Limited
Episode: Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy
Sander Slootweg
Co-founder and managing partner, Forbion
Forbion
Episode: Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing

Hosts

Jeff Cranmer
Executive Editor, BioCentury
Simone Fishburn
Host of The BioCentury Show
Selina Koch
Executive Editor at BioCentury

Reviews

4.7 out of 5 stars from 23 ratings
  • Wow

    Insightful and full of great info every time! Thx!

    Apple Podcasts
    5
    Surfrider182
    United States2 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Insightful interviews with industry leaders and decision-makers.
High-quality guests but sometimes dense for newcomers.
Strong emphasis on translating science to patient impact and market strategy.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets
Q: Before we turn to computation at the Regeneron Genetics Center, how many genetic signals does the RGC generate in a year that make it toward drug development?
About a dozen new signals progress into the pipeline each year, with the team prioritizing the most compelling, well-supported signals and balancing the need to push forward with the risk of overloading development workflows.
Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner
Q: How do biomarkers fit into the ALS drug development toolkit?
Biomarkers such as neurofilament light in serum and phosphorylated neurofilament heavy in CSF provide objective measures of disease activity and treatment response. They help signal whether a therapy is on the right track and may allow earlier assessment of efficacy before traditional clinical outcomes shift.
Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner
Q: What are the main drivers of heterogeneity in ALS that affect trial design?
Heterogeneity comes from mechanistic diversity, progression rate differences among patients, and variability in how patients are assessed. To address this, the field is harmonizing scales, using better prognostic tools like the Tricals model, and incorporating biomarkers to stratify patients and interpret outcomes.
Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking
Q: What drives the rapid dealmaking in China today, and how does Hengrui choose the right deal type for an asset?
Hengrui prioritizes assets with global play and flexibility; licensing remains quick and low-burden, NewCo offers closer governance and faster learning, while CoCo structures enable comprehensive, multi-dimensional collaboration with shared risks and a broader scope across clinical development, preclinical work, and potential discovery.
Ep. 112 - Chris Arendt on rebuilding Takeda for AI
Q: What are the practical implications of faster and slower adopters within the organization, and how does Takeda manage risk when rolling out AI across teams?
Takeda combines top-down endorsement with bottom-up experimentation, forming tiger teams to prototype AI within existing workflows, while maintaining governance that supports rapid experimentation and budgetary autonomy to enable broad participation without stifling progress.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About The BioCentury Show

What is The BioCentury Show about and what kind of topics does it cover?

A deep, executive-level discussion at the intersection of biology, medicine, and biotech investing. Episodes frequently feature CMOs, CEOs, and senior editors analyzing how translational science moves from discovery to patient impact, with a strong emphasis on dealmaking, AI-enabled drug discovery, regulatory enviroments, pricing, and policy. The series often highlights regional dynamics (US, UK, Europe, China) and practical implications for building biotech pipelines, partnerships, and finance strategies. A standout is the recurring focus on creating translational ecosystems that accelerate patient access, from translational science models to large-scale data and AI-enabled platforms. The show is especially noteworthy for its access to bio... more

Where can I find podcast stats for The BioCentury Show?

Rephonic provides a wide range of podcast stats for The BioCentury Show. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to The BioCentury Show and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does The BioCentury Show get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for The BioCentury Show, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for The BioCentury Show?

Rephonic provides comprehensive predictive audience data for The BioCentury Show, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does The BioCentury Show have?

To see how many followers or subscribers The BioCentury Show has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to The BioCentury Show?

These podcasts share a similar audience with The BioCentury Show:

1. BioCentury This Week
2. Biotech Hangout
3. The Long Run with Luke Timmerman
4. The Readout Loud
5. Ground Truths

How many episodes of The BioCentury Show are there?

The BioCentury Show launched 2 years ago and published 72 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact The BioCentury Show?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for The BioCentury Show?

Rephonic pulls ratings and reviews for The BioCentury Show from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for The BioCentury Show?

Rephonic provides full transcripts for episodes of The BioCentury Show. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on The BioCentury Show?

Recent guests on The BioCentury Show include:

1. Nick Galakatos
2. Gonçalo Abecasis
3. Jessica Owens
4. Frank Jiang
5. Chris Arendt
6. Angela Genge
7. Karen Knudsen
8. Chris Hollowood

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days